top of page


Allo-priming as a universal anti-viral vaccine: protecting elderly from current COVID-19 and any future unknown viral outbreak.

Har-Noy M, Or R.J Transl Med. 2020 May 12;18(1):196. doi: 10.1186/s12967-020-02363-3.PMID: 32398026 


The anti-tumor effect of allogeneic bone marrow/stem cell transplant without graft vs. host disease toxicity and without a matched donor requirement?

Har-Noy M, Slavin S.Med Hypotheses. 2008;70(6):1186-92. doi: 10.1016/j.mehy.2007.10.008. Epub 2007 Dec 3.PMID: 18054441


Allogeneic CD3/CD28 cross-linked Th1 memory cells provide potent adjuvant effects for active immunotherapy of leukemia/lymphoma.

Har-Noy M, Zeira M, Weiss L, Fingerut E, Or R, Slavin S.Leuk Res. 2009 Apr;33(4):525-38. doi: 10.1016/j.leukres.2008.08.017. Epub 2008 Oct 1.PMID: 18834631


Completely mismatched allogeneic CD3/CD28 cross-linked Th1 memory cells elicit anti-leukemia effects in unconditioned hosts without GVHD toxicity.

Har-Noy M, Zeira M, Weiss L, Slavin S.Leuk Res. 2008 Dec;32(12):1903-13. doi: 10.1016/j.leukres.2008.05.007. Epub 2008 Jun 18.PMID: 18565579


Th-1 lymphocytes induce dendritic cell tumor killing activity by an IFN-γ-dependent mechanism.

LaCasse CJ, Janikashvili N, Larmonier CB, Alizadeh D, Hanke N, Kartchner J, Situ E, Centuori S, Har-Noy M, Bonnotte B, Katsanis E, Larmonier N.J Immunol. 2011 Dec 15;187(12):6310-7. doi: 10.4049/jimmunol.1101812. Epub 2011 Nov 9.


Allogeneic effector/memory Th-1 cells impair FoxP3+ regulatory T lymphocytes and synergize with chaperone-rich cell lysate vaccine to treat leukemia.

Janikashvili N, LaCasse CJ, Larmonier C, Trad M, Herrell A, Bustamante S, Bonnotte B, Har-Noy M, Larmonier N, Katsanis E.Blood. 2011 Feb 3;117(5):1555-64. doi: 10.1182/blood-2010-06-288621. Epub 2010 Dec 1.PMID: 21123824

Proteomic analyses of different human tumour-derived chaperone-rich cell lysate (CRCL) anti-cancer vaccines reveal antigen content and strong similarities amongst the vaccines along with a basis for CRCL's unique structure: CRCL vaccine proteome leads to unique structure.

Mayer-Sonnenfeld T, Har-Noy M, Lillehei KO, Graner MW.Int J Hyperthermia. 2013 Sep;29(6):520-7. doi: 10.3109/02656736.2013.796529. Epub 2013 Jun 4.PMID: 23734882


Prolonged remission of advanced bronchoalveolar adenocarcinoma in a dog treated with autologous, tumour-derived chaperone-rich cell lysate (CRCL) vaccine.

Epple LM, Bemis LT, Cavanaugh RP, Skope A, Mayer-Sonnenfeld T, Frank C, Olver CS, Lencioni AM, Dusto NL, Tal A, Har-Noy M, Lillehei KO, Katsanis E, Graner MW.Int J Hyperthermia. 2013 Aug;29(5):390-8. doi: 10.3109/02656736.2013.800997. Epub 2013 Jun 20.PMID: 23786302



Response of HER2+ breast cancer patients to allogeneic cell immunotherapy.

DOI: 10.1200/jco.2012.30.15_suppl.e13013 Journal of Clinical Oncology 30, no. 15_suppl


Individualized cancer vaccine to elicit tumor debulking immunity in advanced HCC.

DOI: 10.1200/JCO.2018.36.15_suppl.e15054 Journal of Clinical Oncology 36, no. 15_suppl


Effect of therapeutic vaccine on CTLA4 and tumor debulking response in recurrent and metastatic HNSCC

J Clin Oncol 36, 2018 (suppl 5S; abstr 115).

DOI: 10.1200/JCO.2018.36.5_suppl.115


Phase I/IIb trial: In-situ vaccine for metastatic colorectal cancer.

J Clin Oncol 36, 2018 (suppl 4S; abstr TPS871)

DOI: 10.1200/JCO.2018.36.4_suppl.TPS87


Personalized vaccine for advanced HCC

J Clin Oncol 36, 2018 (suppl 4S; abstr TPS527)


10.1200/JCO.2018.36.4_suppl.TPS527 poster

bottom of page